Cubist Pharmaceuticals (NASDAQ: CBST), Anooraq Resources (NYSE: ANO), Amerigas Partners Lp (NYSE: APU), Ares Capital (NASDAQ: ARCC), Brightpoint (NASDAQ: CELL) and Consolidated Edison (NYSE: ED) ratings and price targets.
Cubist Pharmaceuticals (CBST) had its “buy” rating reiterated by Bank of America (NYSE:BAC).
Anooraq Resources (ANO) was downgraded by Zacks Investment Research from a “neutral” rating to an “underperform” rating.
Amerigas Partners Lp (APU) was downgraded by Zacks Investment Research from a “neutral” rating to an “underperform” rating.
Ares Capital (ARCC) was downgraded by Zacks Investment Research from an “outperform” rating to a “neutral” rating.
Brightpoint (CELL) had its “buy” rating reiterated by Canaccord Genuity.
Consolidated Edison (ED) was downgraded by ISI Group from a “hold” rating to a “sell” rating. They have a price target of $56.00 on the company.
Showing posts with label Cubist Pharmaceuticals. Show all posts
Showing posts with label Cubist Pharmaceuticals. Show all posts
Wednesday, January 11, 2012
Tuesday, January 10, 2012
Cubist (CBST) (ZION) (ALLT) (AMED) (APKT) (ACHN) Ratings, Price Targets
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), Zions Bancorporation (NASDAQ: ZION), Allot Communications Ltd. (NASDAQ: ALLT), Amedisys, Inc. (NASDAQ: AMED), Acme Packet, Inc. (NASDAQ: APKT) and Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) ratings and price targets.
Cubist Pharmaceuticals, Inc. (CBST) had its “buy” rating reiterated by Jefferies Group (NYSE:JEF). They have a price target of $48.00 on the firm.
Zions Bancorporation (ZION) is now covered by BTIG. They have a “neutral” rating on the firm.
Allot Communications Ltd. (ALLT) was downgraded by Zacks Investment Research from an “outperform” rating to a “neutral” rating.
Amedisys, Inc. (AMED) was downgraded by Robert W. Baird from a “neutral” rating to an “underperform” rating. They have a price target of $8.00 on the firm, down from $10.00.
Acme Packet, Inc. (APKT) was downgraded by Zacks Investment Research from a “neutral” rating to an “underperform” rating.
Achillion Pharmaceuticals Inc. (ACHN) had its “buy” rating reiterated by ThinkEquity.
Cubist Pharmaceuticals, Inc. (CBST) had its “buy” rating reiterated by Jefferies Group (NYSE:JEF). They have a price target of $48.00 on the firm.
Zions Bancorporation (ZION) is now covered by BTIG. They have a “neutral” rating on the firm.
Allot Communications Ltd. (ALLT) was downgraded by Zacks Investment Research from an “outperform” rating to a “neutral” rating.
Amedisys, Inc. (AMED) was downgraded by Robert W. Baird from a “neutral” rating to an “underperform” rating. They have a price target of $8.00 on the firm, down from $10.00.
Acme Packet, Inc. (APKT) was downgraded by Zacks Investment Research from a “neutral” rating to an “underperform” rating.
Achillion Pharmaceuticals Inc. (ACHN) had its “buy” rating reiterated by ThinkEquity.
Monday, July 18, 2011
Agilent (A) (AAPL) (BRCM) (BWLD) (CBST) Price Targets Changed
Agilent Technologies Inc. (NYSE: A), Apple, Inc (NASDAQ: AAPL), Broadcom Corp (NASDAQ: BRCM), Buffalo Wild Wings (NASDAQ: BWLD) and Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) price targets changed.
Agilent Technologies Inc. (A) had its price target raised by JPMorgan Chase & Co. (NYSE: JPM) to $63.00.
Apple, Inc (AAPL) had its price target raised by Goldman Sachs (NYSE: GS) to $485.00.
Broadcom Corp. (BRCM) had its price target slashed by Needham & Company from $44.00 to $40.00. They have a “buy” rating on the company.
Buffalo Wild Wings (BWLD) had its price target raised Morgan Keegan to $78.00.
Cubist Pharmaceuticals, Inc. (CBST) had its price target raised by Oppenheimer from $37.00 to $44.00. They have an “outperform” rating on the company.
Agilent Technologies Inc. (A) had its price target raised by JPMorgan Chase & Co. (NYSE: JPM) to $63.00.
Apple, Inc (AAPL) had its price target raised by Goldman Sachs (NYSE: GS) to $485.00.
Broadcom Corp. (BRCM) had its price target slashed by Needham & Company from $44.00 to $40.00. They have a “buy” rating on the company.
Buffalo Wild Wings (BWLD) had its price target raised Morgan Keegan to $78.00.
Cubist Pharmaceuticals, Inc. (CBST) had its price target raised by Oppenheimer from $37.00 to $44.00. They have an “outperform” rating on the company.
J.B. Hunt (JBHT) (BKS) (CBST) (CTSH) (FXCM) Ratings Reiterated
Barnes & Noble Inc (NYSE: BKS), Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), Cognizant (NASDAQ: CTSH), FXCM Inc (NASDAQ: FXCM) and J.B. Hunt Transport Services, Inc. (NASDAQ: JBHT) ratings reiterated by analysts.
Barnes & Noble Inc (BKS) ratings reiterated at an “outperform” by Morgan Keegan.
Cubist Pharmaceuticals, Inc. (CBST) ratings reiterated at “neutral” by Bank of America (NYSE: BAC).
Cognizant (CTSH) ratings reiterated at “overweight” by JPMorgan Chase & Co. (NYSE: JPM).
FXCM (FXCM) ratings reiterated at “overweight” by JPMorgan Chase & Co.. They have a price target of $15.00 on the company.
J.B. Hunt Transport Services, Inc. (JBHT) ratings were reiterated “hold” by Citigroup (NYSE:C).
Barnes & Noble Inc (BKS) ratings reiterated at an “outperform” by Morgan Keegan.
Cubist Pharmaceuticals, Inc. (CBST) ratings reiterated at “neutral” by Bank of America (NYSE: BAC).
Cognizant (CTSH) ratings reiterated at “overweight” by JPMorgan Chase & Co. (NYSE: JPM).
FXCM (FXCM) ratings reiterated at “overweight” by JPMorgan Chase & Co.. They have a price target of $15.00 on the company.
J.B. Hunt Transport Services, Inc. (JBHT) ratings were reiterated “hold” by Citigroup (NYSE:C).
Tuesday, April 5, 2011
Cubist (CBST) Settles with Teva (TEVA) Over Patent Dispute
Cubist Pharmaceuticals (NASDAQ:CBST) announced they've come to a settlement with Teva Pharmaceuticals, Inc. (NASDAQ:TEVA) which allows the Israeli-based drug company to be licensed to produce a generic version of its blockbuster antibiotic, Cubicin. The new generic version could be come to market as early as 2017, according to Cubist.
Terms of the agreement are Teva can launch the new version on June 24, 2018. If Teva is able to secure a six month pediatric exclusivity, the launch date will be moved up to December 24, 2017.
Teva also must acquire ingredients used to develop the drug from Cubist, with the price of source materials including a percentage of Teva's net profit on sales of its generic version, which will be called daptomycin.
The agreement is in relationship solely to the U.S. market, and settles the March 2009 patent case Cubist had brought against Teva.
Teva was trading at $49.97, falling $0.07, or 0.14 percent, as of 9:00 AM EDT. Cubist Pharmaceuticals was soaring at the open, jumping to $28.96, gaining $3.71, or 14.69 percent, as of 9:02 AM EDT.
Terms of the agreement are Teva can launch the new version on June 24, 2018. If Teva is able to secure a six month pediatric exclusivity, the launch date will be moved up to December 24, 2017.
Teva also must acquire ingredients used to develop the drug from Cubist, with the price of source materials including a percentage of Teva's net profit on sales of its generic version, which will be called daptomycin.
The agreement is in relationship solely to the U.S. market, and settles the March 2009 patent case Cubist had brought against Teva.
Teva was trading at $49.97, falling $0.07, or 0.14 percent, as of 9:00 AM EDT. Cubist Pharmaceuticals was soaring at the open, jumping to $28.96, gaining $3.71, or 14.69 percent, as of 9:02 AM EDT.
Tuesday, February 1, 2011
Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN), Human Genome (NASDAQ:HGSI) Could be Takeover Targets
With time and costs a major factor in the drug industry, companies appear to be hunting for takeover targets like Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN) and Human Genome (NASDAQ:HGSI), which have a pipeline, or are close to developing a pipeline, with soon-to-be-approved drugs.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Monday, January 24, 2011
Cubist Pharmaceuticals (NASDAQ:CBST) Driven by Teva Litigation
The narrative going forward for Cubist Pharmaceuticals (NASDAQ:CBST) will primarily be litigation with Teva, and not the rate of growth of Cubicin in 2011; at least for the next several months.
Needham says, "Management appears to have cautiously optimistic expectations for a number of recent and to-be-implemented marketing efforts designed to maintain Cubicin growth in 2011. Our new 2011 U.S. Cubicin sales estimate is $657.0MM. Notwithstanding somewhat low Cubicin sales guidance for this year, litigation with Teva is likely to drive the stock for the next several months. We are generally favorably inclined and believe there is an attractive risk benefit at the stock’s current valuation ($900MM EV).
"Our 2011 and 2012 total revenue estimates are $693.9 (was $697.0MM) and $761.0MM (was $762.0MM). Our new 2011 and 2012 GAAP EPS estimates are $0.85 (was $1.66) and $1.29 (was $1.81), respectively, reflecting accounting items tied to convertible notes and the Calixa earn-out."
Needham & Company maintains a "Buy" rating on Cubist Pharmaceuticals (CBST), which closed Friday at $22.21, gaining $1.01, or 4.76 percent. Needham has a price target on Cubist of $27.
Needham says, "Management appears to have cautiously optimistic expectations for a number of recent and to-be-implemented marketing efforts designed to maintain Cubicin growth in 2011. Our new 2011 U.S. Cubicin sales estimate is $657.0MM. Notwithstanding somewhat low Cubicin sales guidance for this year, litigation with Teva is likely to drive the stock for the next several months. We are generally favorably inclined and believe there is an attractive risk benefit at the stock’s current valuation ($900MM EV).
"Our 2011 and 2012 total revenue estimates are $693.9 (was $697.0MM) and $761.0MM (was $762.0MM). Our new 2011 and 2012 GAAP EPS estimates are $0.85 (was $1.66) and $1.29 (was $1.81), respectively, reflecting accounting items tied to convertible notes and the Calixa earn-out."
Needham & Company maintains a "Buy" rating on Cubist Pharmaceuticals (CBST), which closed Friday at $22.21, gaining $1.01, or 4.76 percent. Needham has a price target on Cubist of $27.
Subscribe to:
Posts (Atom)